SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: DJ who wrote (718)6/15/1999 11:54:00 PM
From: Lel H  Read Replies (1) | Respond to of 1139
 
Leukarrest wasn't Icos's prime pipeline drug

I would have to disagree with you on this point. LeukArrest is most certainly its lead product at this time, and ICOS obviously put a lot of weight in it since it is/was testing it in four independent indications (shock, MI, stroke, MS). So far, two of four looks like busts, though the stroke indication has moved onto phase III. However, as I think I mentioned in the past, there is a long history of failure in the neuroprotective field, so LeukArrest has an uphill battle for this indication.

Regards,
Lel



To: DJ who wrote (718)6/17/1999 6:12:00 PM
From: Dowjoe  Read Replies (1) | Respond to of 1139
 
DJ -why would you pick Stanford ?
This drop is a warning that even companies with brilliant management can get decimated ! & if this is not ICOS biggest item in the pipeline, just think what could happen .....
dowjoe (another DJ)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News